null

Onvatilimab Biosimilar (Anti-B7-H5) Antibody (HDBS0095)

SKU:
HDBS0095
Antibody Type:
Biosimilar Reference Antibody
Applications:
IHC
FC
Drug Development
Pharmacokinetics
Disease Area:
Cancer
Protein:
B7-H5
Reactivity:
Human
Host Species:
Humanized
Isotype:
IgG1
€399

Description

system_update_altDatasheet

Onvatilimab (Anti-B7-H5) Biosimilar Antibody (HDBS0095)

The OnvatiLimab Biosimilar Anti-B7-H5 Antibody is a cutting-edge product designed for research involving B7-H5, a cell surface molecule involved in immune regulation and immune checkpoint pathways. This biosimilar antibody, derived from innovative biotechnology, is highly specific and reactive with human samples, making it ideal for in vitro studies and preclinical research.The B7-H5 protein, also known as V-domain Ig suppressor of T cell activation (VISTA), plays a crucial role in regulating T cell function and maintaining immune tolerance. It has been identified as a potential target for cancer immunotherapy and autoimmune disease treatment. The OnvatiLimab Biosimilar Anti-B7-H5 Antibody allows for the detection and analysis of B7-H5 protein expression in various cell types, providing valuable insights for immunology and oncology research.

Researchers and pharmaceutical companies can utilize this advanced antibody to further explore the mechanisms of immune evasion and immune suppression in cancer and autoimmune disorders. By understanding the role of B7-H5 in immune response modulation, innovative therapeutic strategies can be developed to enhance immune surveillance or restore immune balance in disease settings. Unlock the potential of B7-H5 research with the OnvatiLimab Biosimilar Anti-B7-H5 Antibody.